Evidence map›Paper›PMID 30014756›Full record

ArticleInternational journal of immunopathology and pharmacology

Bicyclic eremophilane-type petasite sesquiterpenes potentiate peroxisome proliferator-activated receptor γ activator-mediated inhibition of dendritic cells.

Narcy Arizmendi, Chenjie Hou, Fujiang Guo, Yiming Li, Marianna Kulka

Open access · goldAbstract read
In one paragraph

Article in International journal of immunopathology and pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Narcy Arizmendi1 Nanotechnology Research Center, National Research Council Canada, Edmonton, AB, Canada.ORCID https://orcid.org/0000-0003-4562-7432
Chenjie Hou2 School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Fujiang Guo2 School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yiming Li2 School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Marianna Kulka1 Nanotechnology Research Center, National Research Council Canada, Edmonton, AB, Canada.
Shanghai University of Traditional Chinese Medicine · CNNational Institute for Nanotechnology · CAUniversity of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dendritic cell (DC) activation induces expression of co-stimulatory surface molecules, as well as migration into secondary lymphoid organs, where they activate naïve T-cells. A family of plant derivatives, eremophilane-type petasite sesquiterpenes, can regulate the immune system through DC targeting due to their anti-inflammatory effects. Peroxisome proliferator-activated receptor gamma (PPARγ) is involved in inhibition of inflammatory responses and induction of DCs to acquire a mucosal phenotype. Since mucosal DCs are central in innate immune responses, we hypothesized that eremophilane-type petasite sesquiterpenes exerted their anti-inflammatory effects by inhibiting DC maturation and activation through PPARγ. This study assessed the bicyclic eremophilane-type petasite sesquiterpene compounds Fukinone and 10βH-8α,12-Epidioxyeremophil-7(11)-en-8β-ol (ZYFDC21 and ZYFDC22) in the maturation and activation of mouse DC. We measured surface expression of co-stimulatory molecules by flow cytometry and cell-free supernatant cytokine production upon lipopolysaccharide stimulation by enzyme-linked immunosorbent assays (ELISAs) in the presence or absence of PPARγ agonists. DCs were generated from C57BL/6 mice bone marrow cells and harvested. Cells were exposed to bicyclic eremophilane-type petasite sesquiterpenes ZYFDC21 or ZYFDC22 in the presence or absence of synthetic PPARγ agonists (GW1929 and TGZ) or the natural PPARγ ligand 15d-PGJ

Indexed as

AnimalsAnti-Inflammatory AgentsBenzophenonesBone Marrow CellsCells, CulturedCytokinesDendritic CellsDrug SynergismFemaleLipopolysaccharidesMice, Inbred C57BLPolycyclic SesquiterpenesPPAR gammaProstaglandin D2SesquiterpenesTroglitazone15-deoxyprostaglandin J2Anti-Inflammatory AgentsBenzophenonesCytokineseremophilane compoundsGW 1929LipopolysaccharidesPolycyclic SesquiterpenesPPAR gammaProstaglandin D2SesquiterpenesTroglitazoneTyrosineinflammationperoxisome proliferator–activated receptor gammaplant derivativestranscription factor

Identifiers

PMID30014756
PMCPMC6050815
OpenAlexW2799536686

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.